Stress-induced insomnia: opioid-dopamine interactions.
REM sleep deprivation induced by means of the platform technique (72 h) was followed by a period of latency to sleep characterized by a marked excitement in rats. The administration of naloxone at the end of the REM deprivation period reduced this latency to sleep while morphine, beta-endorphin and DADLE prolonged it. The dopamine D1 receptor antagonist SCH 23390 was extremely potent (0.003 mg/kg) to reduce the latency to sleep and the excitement while the D1 agonist SKF 38393 induced an opposite effect. The dopamine D2 receptor antagonist L-sulpiride was inactive up to a dose of 25 mg/kg. These data suggest that hyperactivity of the opioid and dopamine systems (specifically mediated through D1 receptors) is involved in such behaviour.
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001067:Appetite Depressants / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000502:physiology*; D011957:Receptors, Opioid / Q000502:physiology*; D012892:Sleep Deprivation / Q000502:physiology; D007319:Sleep Initiation and Maintenance Disorders / Q000209:etiology / Q000503:physiopathology*; D012895:Sleep, REM / Q000502:physiology; D013315:Stress, Psychological / Q000150:complications*; D013469:Sulpiride / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D014150:Antipsychotic Agents; D001067:Appetite Depressants; D001552:Benzazepines; D011954:Receptors, Dopamine; D011957:Receptors, Opioid; D009270:Naloxone; D005680:gamma-Aminobutyric Acid; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D013469:Sulpiride; D006220:Haloperidol